Clinical Trial: N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy

U.S., Dec. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07279610) titled 'N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy' on Dec. 01.

Brief Summary: This multicenter, prospective, single-arm clinical trial aims to evaluate the efficacy and safety of N-acetylcysteine (NAC) for treating Transplantation-Associated Thrombotic Microangiopathy (TA-TMA), a severe complication of hematopoietic stem cell transplantation characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ injury, with an incidence of 4%-30%. Current treatments, including plasma exchange (response rate <10%) and costly complement inhibitors like Eculizumab (71% response) which are n...